Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
waveLINE-003: zilovertamab vedotin plus standard of care for relapsed or refractory diffuse large B-cell lymphoma
2022-502646-27-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with dose-limiting toxicities, Percentage of participants with adverse events and 3 more. Planned start Jun 2022; status: authorised.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-502646-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502646-27-00.